help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goerdt, S.
Right arrow Articles by Sorg, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goerdt, S.
Right arrow Articles by Sorg, C.

American Journal of Pathology, Vol 142, 1409-1422, Copyright © 1993 by American Society for Investigative Pathology


REGULAR ARTICLES

Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro

S Goerdt, R Bhardwaj and C Sorg
Klinik und Poliklinik fur Hautkrankheiten, Westfalische Wilhelms- Universitat, Munster/Westfalen, Germany.

Recently, we have described a monoclonal antibody, named MS-1, which identifies a novel high-molecular-weight protein expressed by noncontinuous, sinusoidal endothelia and by interstitial dendritic cells in certain normal human organs (S Goerdt, LJ Walsh, GF Murphy, JS Pober, J Cell Biol 1991, 113:1425-1437; and LJ Walsh, S Goerdt, JS Pober, H Sueki, GF Murphy, Lab Invest 1991, 65: 732-741). In this report, we demonstrate in studying a variety of skin lesions that MS-1 antigen can also be expressed by endothelia of continuous origin under certain pathological conditions. Among the skin lesions tested, MS-1 antigen expression by endothelial cells of continuous origin is frequently observed in wound healing tissue, in cutaneous T-cell lymphoma, in psoriasis, and in melanoma metastasis, ie, in 100%, 80%, 71%, and 71% of cases, respectively. In contrast, endothelial MS-1 antigen expression rarely occurred in other skin lesions, including vascular tumors, six of which were Kaposi's sarcomas (13% and 0% of cases with vascular MS-1 expression, respectively). The percentage of cases with MS-1+ vessels is only marginally different in malignant versus benign lesions (55% versus 31%); when melanocytic nevi, primary melanomas, and melanoma metastases are compared, however, an increase in the percentage of cases with MS-1+ vessels is seen (31%, 50%, and 71%, respectively). Apart from wound healing, the relative number of MS- 1+ vessels in a given lesion amounts to less than 5% compared with the number of continuous type vessels stained by monoclonal antibody 1F10 (S Goerdt, F Steckel, K Schulze-Osthoff, H-H Hagemeier, E Macher, C Sorg, Exp Cell Biol 1989, 57: 185-192). In addition, the occurrence of MS-1+ vessels is not related to the overall vascularity of a given lesion. Thus, the conditions for MS-1 antigen expression by endothelia of continuous origin cannot as yet be exactly defined. Furthermore, we have noticed that the number of MS-1+ dendritic cells varies considerably in skin lesions; in the early patch lesions of Kaposi's sarcoma and in juvenile xanthogranuloma MS-1+ cells even constitute the major cell type. This prompted us to investigate MS-1 antigen expression and its regulation in cultured human monocytes/macrophages. Expression of MS-1 antigen by these cells regularly starts at day 3 of culture and reaches its maximal value at day 9, after which it declines.(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
J. Immunol.Home page
J. Kzhyshkowska, A. Gratchev, C. Schmuttermaier, H. Brundiers, L. Krusell, S. Mamidi, J. Zhang, G. Workman, E. H. Sage, C. Anderle, et al.
Alternatively Activated Macrophages Regulate Extracellular Levels of the Hormone Placental Lactogen via Receptor-Mediated Uptake and Transcytosis
J. Immunol., March 1, 2008; 180(5): 3028 - 3037.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Kzhyshkowska, G. Workman, M. Cardo-Vila, W. Arap, R. Pasqualini, A. Gratchev, L. Krusell, S. Goerdt, and E. H. Sage
Novel Function of Alternatively Activated Macrophages: Stabilin-1-Mediated Clearance of SPARC
J. Immunol., May 15, 2006; 176(10): 5825 - 5832.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Salmi, K. Koskinen, T. Henttinen, K. Elima, and S. Jalkanen
CLEVER-1 mediates lymphocyte transmigration through vascular and lymphatic endothelium
Blood, December 15, 2004; 104(13): 3849 - 3857.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Prevo, S. Banerji, J. Ni, and D. G. Jackson
Rapid Plasma Membrane-Endosomal Trafficking of the Lymph Node Sinus and High Endothelial Venule Scavenger Receptor/Homing Receptor Stabilin-1 (Feel-1/Clever-1)
J. Biol. Chem., December 10, 2004; 279(50): 52580 - 52592.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
J. Kzhyshkowska, A. Gratchev, J.-H. Martens, O. Pervushina, S. Mamidi, S. Johansson, K. Schledzewski, B. Hansen, X. He, J. Tang, et al.
Stabilin-1 localizes to endosomes and the trans-Golgi network in human macrophages and interacts with GGA adaptors
J. Leukoc. Biol., December 1, 2004; 76(6): 1151 - 1161.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. Raes, P. De Baetselier, W. Noel, A. Beschin, F. Brombacher, and G. Hassanzadeh Gh.
Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages
J. Leukoc. Biol., April 1, 2002; 71(4): 597 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. Kodelja, C. Muller, O. Politz, N. Hakij, C. E. Orfanos, and S. Goerdt
Alternative Macrophage Activation-Associated CC-Chemokine-1, a Novel Structural Homologue of Macrophage Inflammatory Protein-1{alpha} with a Th2-Associated Expression Pattern
J. Immunol., February 1, 1998; 160(3): 1411 - 1418.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Society for Investigative Pathology.